Market capitalization | $15.06b |
Enterprise Value | $15.63b |
P/E (TTM) P/E ratio | 39.00 |
EV/FCF (TTM) EV/FCF | 81.85 |
EV/Sales (TTM) EV/Sales | 8.35 |
P/S ratio (TTM) P/S ratio | 8.04 |
P/B ratio (TTM) P/B ratio | 15.08 |
Revenue growth (TTM) Revenue growth | 27.82% |
Revenue (TTM) Revenue | $1.87b |
As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.
24 Analysts have issued a Insulet Corporation forecast:
24 Analysts have issued a Insulet Corporation forecast:
Jun '24 |
+/-
%
|
||
Revenue | 1,873 1,873 |
28%
28%
|
|
Gross Profit | 1,303 1,303 |
44%
44%
|
|
EBITDA | 348 348 |
134%
134%
|
EBIT (Operating Income) EBIT | 273 273 |
220%
220%
|
Net Profit | 395 395 |
528%
528%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Insulet Corp. is a medical device company. The firm engages in the development, manufacture and marketing of an insulin infusion system for people with insulin-dependent diabetes. It specializes in diabetes supplies, including the OmniPod System as well as other diabetes related products and supplies such as blood glucose testing supplies, traditional insulin pumps, pump supplies, and pharmaceuticals. The company was founded by John L. Brooks III and John T. Garibotto in July 2000 and is headquartered in Acton, MA.
Head office | United States |
CEO | James Hollingshead |
Employees | 3,000 |
Founded | 2000 |
Website | www.insulet.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.